25 XP   0   0   10

Immutep Ltd
Buy, Hold or Sell?

Let's analyse Immutep together

PenkeI guess you are interested in Immutep Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Immutep Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Immutep Ltd

I send you an email if I find something interesting about Immutep Ltd.

Quick analysis of Immutep (30 sec.)










What can you expect buying and holding a share of Immutep? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$0.11
Expected worth in 1 year
A$0.26
How sure are you?
70.0%

+ What do you gain per year?

Total Gains per Share
A$0.14
Return On Investment
38.0%

For what price can you sell your share?

Current Price per Share
A$0.38
Expected price per share
A$0.325 - A$0.42822209302326
How sure are you?
50%

1. Valuation of Immutep (5 min.)




Live pricePrice per Share (EOD)

A$0.38

Intrinsic Value Per Share

A$-0.43 - A$-0.19

Total Value Per Share

A$-0.32 - A$-0.07

2. Growth of Immutep (5 min.)




Is Immutep growing?

Current yearPrevious yearGrowGrow %
How rich?$88.2m$60.8m$27.4m31.1%

How much money is Immutep making?

Current yearPrevious yearGrowGrow %
Making money-$25.8m-$20.8m-$4.9m-19.3%
Net Profit Margin-1,138.0%-18,906.5%--

How much money comes from the company's main activities?

3. Financial Health of Immutep (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#404 / 1020

Most Revenue
#440 / 1020

Most Profit
#740 / 1020

Most Efficient
#821 / 1020

What can you expect buying and holding a share of Immutep? (5 min.)

Welcome investor! Immutep's management wants to use your money to grow the business. In return you get a share of Immutep.

What can you expect buying and holding a share of Immutep?

First you should know what it really means to hold a share of Immutep. And how you can make/lose money.

Speculation

The Price per Share of Immutep is A$0.375. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Immutep.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Immutep, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.11. Based on the TTM, the Book Value Change Per Share is A$0.04 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Immutep.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.02-5.8%-0.02-5.8%-0.02-4.7%-0.01-3.9%-0.01-3.8%
Usd Book Value Change Per Share0.026.1%0.026.1%0.013.0%0.013.0%0.011.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.026.1%0.026.1%0.013.0%0.013.0%0.011.6%
Usd Price Per Share0.20-0.20-0.19-0.17-0.10-
Price to Earnings Ratio-9.39--9.39--10.70--11.45--7.04-
Price-to-Total Gains Ratio8.83-8.83-16.57-11.84-9.38-
Price to Book Ratio2.74-2.74-3.66-4.42-3.10-
Price-to-Total Gains Ratio8.83-8.83-16.57-11.84-9.38-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.2425125
Number of shares4123
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.020.01
Usd Total Gains Per Share0.020.01
Gains per Quarter (4123 shares)95.0846.18
Gains per Year (4123 shares)380.31184.71
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
103803700185175
207617500369360
30114111300554545
40152115100739730
50190218900924915
6022822270011081100
7026622650012931285
8030423030014781470
9034233410016621655
10038033790018471840

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.016.08.00.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%7.03.00.070.0%14.010.00.058.3%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.024.00.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%7.03.00.070.0%14.010.00.058.3%

Fundamentals of Immutep

About Immutep Ltd

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Fundamental data was last updated by Penke on 2024-03-31 22:05:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Immutep Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Immutep earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Immutep to the Biotechnology industry mean.
  • A Net Profit Margin of -1,138.0% means that $-11.38 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Immutep Ltd:

  • The MRQ is -1,138.0%. The company is making a huge loss. -2
  • The TTM is -1,138.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,138.0%TTM-1,138.0%0.0%
TTM-1,138.0%YOY-18,906.5%+17,768.5%
TTM-1,138.0%5Y-6,527.7%+5,389.7%
5Y-6,527.7%10Y-7,150.0%+622.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,138.0%-206.1%-931.9%
TTM-1,138.0%-214.1%-923.9%
YOY-18,906.5%-279.3%-18,627.2%
5Y-6,527.7%-457.4%-6,070.3%
10Y-7,150.0%-634.2%-6,515.8%
1.1.2. Return on Assets

Shows how efficient Immutep is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Immutep to the Biotechnology industry mean.
  • -27.1% Return on Assets means that Immutep generated $-0.27 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Immutep Ltd:

  • The MRQ is -27.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -27.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-27.1%TTM-27.1%0.0%
TTM-27.1%YOY-31.5%+4.5%
TTM-27.1%5Y-32.8%+5.8%
5Y-32.8%10Y-52.0%+19.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-27.1%-14.8%-12.3%
TTM-27.1%-14.1%-13.0%
YOY-31.5%-12.8%-18.7%
5Y-32.8%-16.0%-16.8%
10Y-52.0%-17.6%-34.4%
1.1.3. Return on Equity

Shows how efficient Immutep is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Immutep to the Biotechnology industry mean.
  • -29.2% Return on Equity means Immutep generated $-0.29 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Immutep Ltd:

  • The MRQ is -29.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -29.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-29.2%TTM-29.2%0.0%
TTM-29.2%YOY-34.2%+5.0%
TTM-29.2%5Y-42.3%+13.1%
5Y-42.3%10Y-65.0%+22.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-29.2%-18.4%-10.8%
TTM-29.2%-16.9%-12.3%
YOY-34.2%-17.9%-16.3%
5Y-42.3%-21.9%-20.4%
10Y-65.0%-23.1%-41.9%

1.2. Operating Efficiency of Immutep Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Immutep is operating .

  • Measures how much profit Immutep makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Immutep to the Biotechnology industry mean.
  • An Operating Margin of -1,281.8% means the company generated $-12.82  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Immutep Ltd:

  • The MRQ is -1,281.8%. The company is operating very inefficient. -2
  • The TTM is -1,281.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,281.8%TTM-1,281.8%0.0%
TTM-1,281.8%YOY-19,920.0%+18,638.2%
TTM-1,281.8%5Y-7,305.8%+6,023.9%
5Y-7,305.8%10Y-7,619.5%+313.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,281.8%-287.7%-994.1%
TTM-1,281.8%-242.2%-1,039.6%
YOY-19,920.0%-288.4%-19,631.6%
5Y-7,305.8%-480.7%-6,825.1%
10Y-7,619.5%-637.5%-6,982.0%
1.2.2. Operating Ratio

Measures how efficient Immutep is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 12.82 means that the operating costs are $12.82 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Immutep Ltd:

  • The MRQ is 12.818. The company is inefficient in keeping operating costs low. -1
  • The TTM is 12.818. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ12.818TTM12.8180.000
TTM12.818YOY211.724-198.906
TTM12.8185Y98.306-85.488
5Y98.30610Y92.708+5.599
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.8183.230+9.588
TTM12.8183.283+9.535
YOY211.7243.832+207.892
5Y98.3065.741+92.565
10Y92.7087.992+84.716

1.3. Liquidity of Immutep Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Immutep is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 13.81 means the company has $13.81 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Immutep Ltd:

  • The MRQ is 13.811. The company is very able to pay all its short-term debts. +2
  • The TTM is 13.811. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ13.811TTM13.8110.000
TTM13.811YOY14.157-0.346
TTM13.8115Y10.897+2.915
5Y10.89710Y9.343+1.554
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.8113.986+9.825
TTM13.8114.269+9.542
YOY14.1575.498+8.659
5Y10.8975.971+4.926
10Y9.3436.408+2.935
1.3.2. Quick Ratio

Measures if Immutep is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Immutep to the Biotechnology industry mean.
  • A Quick Ratio of 13.45 means the company can pay off $13.45 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Immutep Ltd:

  • The MRQ is 13.445. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 13.445. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ13.445TTM13.4450.000
TTM13.445YOY13.776-0.331
TTM13.4455Y10.515+2.931
5Y10.51510Y9.284+1.231
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.4453.757+9.688
TTM13.4454.124+9.321
YOY13.7765.504+8.272
5Y10.5155.943+4.572
10Y9.2846.225+3.059

1.4. Solvency of Immutep Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Immutep assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Immutep to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.07 means that Immutep assets are financed with 7.4% credit (debt) and the remaining percentage (100% - 7.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Immutep Ltd:

  • The MRQ is 0.074. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.074. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.074TTM0.0740.000
TTM0.074YOY0.079-0.005
TTM0.0745Y0.189-0.114
5Y0.18910Y0.196-0.007
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0740.328-0.254
TTM0.0740.326-0.252
YOY0.0790.266-0.187
5Y0.1890.370-0.181
10Y0.1960.396-0.200
1.4.2. Debt to Equity Ratio

Measures if Immutep is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Immutep to the Biotechnology industry mean.
  • A Debt to Equity ratio of 8.0% means that company has $0.08 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Immutep Ltd:

  • The MRQ is 0.080. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.080. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.080TTM0.0800.000
TTM0.080YOY0.086-0.006
TTM0.0805Y0.270-0.189
5Y0.27010Y0.265+0.004
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0800.371-0.291
TTM0.0800.384-0.304
YOY0.0860.328-0.242
5Y0.2700.423-0.153
10Y0.2650.450-0.185

2. Market Valuation of Immutep Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Immutep generates.

  • Above 15 is considered overpriced but always compare Immutep to the Biotechnology industry mean.
  • A PE ratio of -9.39 means the investor is paying $-9.39 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Immutep Ltd:

  • The EOD is -11.174. Based on the earnings, the company is expensive. -2
  • The MRQ is -9.386. Based on the earnings, the company is expensive. -2
  • The TTM is -9.386. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-11.174MRQ-9.386-1.788
MRQ-9.386TTM-9.3860.000
TTM-9.386YOY-10.703+1.317
TTM-9.3865Y-11.452+2.065
5Y-11.45210Y-7.038-4.413
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-11.174-2.543-8.631
MRQ-9.386-2.591-6.795
TTM-9.386-2.669-6.717
YOY-10.703-4.234-6.469
5Y-11.452-6.310-5.142
10Y-7.038-6.212-0.826
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Immutep Ltd:

  • The EOD is -12.408. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -10.423. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -10.423. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-12.408MRQ-10.423-1.985
MRQ-10.423TTM-10.4230.000
TTM-10.423YOY-11.396+0.974
TTM-10.4235Y-15.552+5.130
5Y-15.55210Y-10.358-5.194
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-12.408-3.382-9.026
MRQ-10.423-3.363-7.060
TTM-10.423-3.653-6.770
YOY-11.396-5.822-5.574
5Y-15.552-8.477-7.075
10Y-10.358-8.811-1.547
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Immutep is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.74 means the investor is paying $2.74 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Immutep Ltd:

  • The EOD is 3.267. Based on the equity, the company is fair priced.
  • The MRQ is 2.744. Based on the equity, the company is underpriced. +1
  • The TTM is 2.744. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.267MRQ2.744+0.523
MRQ2.744TTM2.7440.000
TTM2.744YOY3.665-0.921
TTM2.7445Y4.417-1.673
5Y4.41710Y3.096+1.321
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.2672.030+1.237
MRQ2.7442.133+0.611
TTM2.7442.124+0.620
YOY3.6652.943+0.722
5Y4.4173.477+0.940
10Y3.0963.682-0.586
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Immutep Ltd.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Immutep Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0360.0360%0.018+104%0.017+106%0.009+295%
Book Value Per Share--0.1150.1150%0.079+45%0.061+89%0.042+171%
Current Ratio--13.81113.8110%14.157-2%10.897+27%9.343+48%
Debt To Asset Ratio--0.0740.0740%0.079-6%0.189-61%0.196-62%
Debt To Equity Ratio--0.0800.0800%0.086-6%0.270-70%0.265-70%
Dividend Per Share----0%-0%-0%-0%
Eps---0.034-0.0340%-0.027-19%-0.023-33%-0.022-34%
Free Cash Flow Per Share---0.030-0.0300%-0.025-16%-0.019-39%-0.013-56%
Free Cash Flow To Equity Per Share--0.0340.0340%0.017+100%0.016+106%0.009+265%
Gross Profit Margin--1.1351.1350%1.000+14%1.027+11%1.014+12%
Intrinsic Value_10Y_max---0.188--------
Intrinsic Value_10Y_min---0.433--------
Intrinsic Value_1Y_max---0.015--------
Intrinsic Value_1Y_min---0.029--------
Intrinsic Value_3Y_max---0.047--------
Intrinsic Value_3Y_min---0.100--------
Intrinsic Value_5Y_max---0.084--------
Intrinsic Value_5Y_min---0.184--------
Market Cap445811232.000+16%374481434.880374481434.8800%344760686.080+9%317417597.184+18%182842046.618+105%
Net Profit Margin---11.380-11.3800%-189.065+1561%-65.277+474%-71.500+528%
Operating Margin---12.818-12.8180%-199.200+1454%-73.058+470%-76.195+494%
Operating Ratio--12.81812.8180%211.724-94%98.306-87%92.708-86%
Pb Ratio3.267+16%2.7442.7440%3.665-25%4.417-38%3.096-11%
Pe Ratio-11.174-19%-9.386-9.3860%-10.703+14%-11.452+22%-7.038-25%
Price Per Share0.375+16%0.3150.3150%0.290+9%0.267+18%0.154+105%
Price To Free Cash Flow Ratio-12.408-19%-10.423-10.4230%-11.396+9%-15.552+49%-10.358-1%
Price To Total Gains Ratio10.516+16%8.8348.8340%16.570-47%11.837-25%9.382-6%
Quick Ratio--13.44513.4450%13.776-2%10.515+28%9.284+45%
Return On Assets---0.271-0.2710%-0.315+17%-0.328+21%-0.520+92%
Return On Equity---0.292-0.2920%-0.342+17%-0.423+45%-0.650+122%
Total Gains Per Share--0.0360.0360%0.018+104%0.017+106%0.009+295%
Usd Book Value--88254753.86688254753.8660%60839832.592+45%46757111.928+89%32603977.792+171%
Usd Book Value Change Per Share--0.0230.0230%0.011+104%0.011+106%0.006+295%
Usd Book Value Per Share--0.0740.0740%0.051+45%0.039+89%0.027+171%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.022-0.0220%-0.018-19%-0.015-33%-0.014-34%
Usd Free Cash Flow---23235931.000-23235931.0000%-19564399.102-16%-14230650.056-39%-10336225.760-56%
Usd Free Cash Flow Per Share---0.020-0.0200%-0.016-16%-0.012-39%-0.009-56%
Usd Free Cash Flow To Equity Per Share--0.0220.0220%0.011+100%0.011+106%0.006+265%
Usd Market Cap288306123.734+16%242177143.937242177143.9370%222956735.688+9%205273960.099+18%118243951.548+105%
Usd Price Per Share0.243+16%0.2040.2040%0.188+9%0.173+18%0.099+105%
Usd Profit---25800968.252-25800968.2520%-20830741.174-19%-17040373.107-34%-16902937.458-34%
Usd Revenue--2267150.4172267150.4170%110177.632+1958%1961457.009+16%1666311.730+36%
Usd Total Gains Per Share--0.0230.0230%0.011+104%0.011+106%0.006+295%
 EOD+6 -2MRQTTM+0 -0YOY+22 -125Y+24 -1010Y+26 -8

4.2. Fundamental Score

Let's check the fundamental score of Immutep Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-11.174
Price to Book Ratio (EOD)Between0-13.267
Net Profit Margin (MRQ)Greater than0-11.380
Operating Margin (MRQ)Greater than0-12.818
Quick Ratio (MRQ)Greater than113.445
Current Ratio (MRQ)Greater than113.811
Debt to Asset Ratio (MRQ)Less than10.074
Debt to Equity Ratio (MRQ)Less than10.080
Return on Equity (MRQ)Greater than0.15-0.292
Return on Assets (MRQ)Greater than0.05-0.271
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Immutep Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.639
Ma 20Greater thanMa 500.383
Ma 50Greater thanMa 1000.370
Ma 100Greater thanMa 2000.351
OpenGreater thanClose0.375
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets147,449
Total Liabilities10,980
Total Stockholder Equity136,469
 As reported
Total Liabilities 10,980
Total Stockholder Equity+ 136,469
Total Assets = 147,449

Assets

Total Assets147,449
Total Current Assets134,965
Long-term Assets12,484
Total Current Assets
Cash And Cash Equivalents 123,418
Net Receivables 7,973
Other Current Assets 3,574
Total Current Assets  (as reported)134,965
Total Current Assets  (calculated)134,965
+/-0
Long-term Assets
Property Plant Equipment 469
Goodwill 110
Intangible Assets 9,380
Long-term Assets Other 2,525
Long-term Assets  (as reported)12,484
Long-term Assets  (calculated)12,484
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities9,772
Long-term Liabilities1,207
Total Stockholder Equity136,469
Total Current Liabilities
Short-term Debt 185
Accounts payable 5,448
Other Current Liabilities 4,139
Total Current Liabilities  (as reported)9,772
Total Current Liabilities  (calculated)9,772
+/-0
Long-term Liabilities
Long term Debt Total 1,043
Other Liabilities 164
Long-term Liabilities  (as reported)1,207
Long-term Liabilities  (calculated)1,207
+/- 0
Total Stockholder Equity
Common Stock446,272
Retained Earnings -339,931
Accumulated Other Comprehensive Income 30,128
Total Stockholder Equity (as reported)136,469
Total Stockholder Equity (calculated)136,469
+/-0
Other
Capital Stock446,272
Cash And Equivalents3,588
Cash and Short Term Investments 123,418
Common Stock Shares Outstanding 880,213
Liabilities and Stockholders Equity 147,449
Net Debt -122,189
Net Invested Capital 137,305
Net Tangible Assets 126,979
Net Working Capital 125,193
Property Plant and Equipment Gross 1,113
Short Long Term Debt Total 1,228



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-302000-06-30
> Total Assets 
2,095
4,244
5,926
3,968
5,768
9,131
7,360
4,358
2,821
2,490
19,011
57,641
41,613
32,814
25,378
30,983
42,554
34,964
46,999
40,541
46,597
82,031
102,170
147,449
147,449102,17082,03146,59740,54146,99934,96442,55430,98325,37832,81441,61357,64119,0112,4902,8214,3587,3609,1315,7683,9685,9264,2442,095
   > Total Current Assets 
0
0
0
0
0
0
0
0
1,181
1,373
16,774
57,063
40,903
31,808
24,684
8,023
21,671
15,919
28,643
23,542
31,152
68,419
90,812
134,965
134,96590,81268,41931,15223,54228,64315,91921,6718,02324,68431,80840,90357,06316,7741,3731,18100000000
       Cash And Cash Equivalents 
687
2,992
3,715
1,579
2,785
7,533
3,211
672
1,109
951
15,641
45,931
17,005
22,023
14,200
6,760
20,880
12,237
23,476
16,568
26,322
60,128
79,995
123,418
123,41879,99560,12826,32216,56823,47612,23720,8806,76014,20022,02317,00545,93115,6419511,1096723,2117,5332,7851,5793,7152,992687
       Short-term Investments 
0
50
0
0
0
0
0
0
0
0
10,000
10,000
21,045
8,000
9,000
0
0
0
0
0
0
0
0
0
0000000009,0008,00021,04510,00010,00000000000500
       Net Receivables 
118
149
34
66
603
77
112
33
71
357
428
420
793
357
362
861
169
2,194
3,482
5,231
3,392
6,124
8,374
7,973
7,9738,3746,1243,3925,2313,4822,1941698613623577934204283577133112776036634149118
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
214
192
0
0
0
0
0
0
0
0
465
-1,108
0
0-1,1084650000000019221400000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
1,640
1,116
2,237
578
710
1,006
694
22,960
20,883
19,045
18,356
17,000
15,445
13,611
11,358
12,484
12,48411,35813,61115,44517,00018,35619,04520,88322,9606941,0067105782,2371,1161,64000000000
       Property Plant Equipment 
1,265
9
63
67
61
47
51
47
30
19
97
120
484
835
577
298
32
24
26
53
251
310
308
469
4693083102515326243229857783548412097193047514761676391,265
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
110
110
110
110
110
110
110
110
110
110110110110110110110110110000000000000000
       Intangible Assets 
0
1,044
2,055
2,256
2,299
1,266
668
626
584
542
500
458
226
171
117
22,552
20,742
18,910
18,219
16,837
15,085
12,737
10,444
9,380
9,38010,44412,73715,08516,83718,21918,91020,74222,5521171712264585005425846266681,2662,2992,2562,0551,0440
       Other Assets 
0
0
50
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
454
496
2,525
2,5254964540000000000000000005000
> Total Liabilities 
219
102
466
875
641
788
1,043
278
188
677
2,224
2,542
4,455
3,566
2,786
6,294
7,237
8,431
13,477
16,154
13,298
8,759
8,092
10,980
10,9808,0928,75913,29816,15413,4778,4317,2376,2942,7863,5664,4552,5422,2246771882781,043788641875466102219
   > Total Current Liabilities 
189
101
466
873
638
775
1,026
261
188
677
2,223
2,537
4,444
3,560
2,771
4,380
1,472
2,632
3,853
5,299
3,364
5,340
6,414
9,772
9,7726,4145,3403,3645,2993,8532,6321,4724,3802,7713,5604,4442,5372,2236771882611,026775638873466101189
       Short-term Debt 
0
0
0
0
0
0
0
0
0
240
700
10,000
21,045
8,000
9,000
1,508
0
5,779
6,646
0
129
208
173
185
18517320812906,6465,77901,5089,0008,00021,04510,000700240000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,508
0
5,779
6,646
0
0
0
0
0
000006,6465,77901,508000000000000000
       Accounts payable 
164
0
466
191
288
378
409
122
119
116
1,352
1,770
2,724
3,087
2,217
2,202
561
1,139
1,615
2,557
1,640
1,825
2,866
5,448
5,4482,8661,8251,6402,5571,6151,1395612,2022,2173,0872,7241,7701,3521161191224093782881914660164
       Other Current Liabilities 
25
101
0
682
349
396
617
139
69
321
171
767
1,720
473
554
669
911
1,493
2,238
2,742
1,595
3,307
3,375
4,139
4,1393,3753,3071,5952,7422,2381,4939116695544731,72076717132169139617396349682010125
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
1
4
10
6
15
1,914
5,765
5,799
9,623
10,855
9,934
3,419
1,678
1,207
1,2071,6783,4199,93410,8559,6235,7995,7651,91415610410000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,027
5,779
6,646
7,643
8,922
2,607
1,560
1,043
1,0431,5602,6078,9227,6436,6465,7795,0270000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
-240
-700
-10,000
-21,045
-8,000
-9,000
-1,508
0
-5,779
-6,646
0
133
80
235
208
208235801330-6,646-5,7790-1,508-9,000-8,000-21,045-10,000-700-240000000000
> Total Stockholder Equity
1,876
3,131
4,337
3,093
5,066
8,343
6,316
4,080
2,633
1,813
16,788
55,099
37,158
29,248
22,592
24,690
35,318
26,532
33,522
24,388
33,299
73,272
94,077
136,469
136,46994,07773,27233,29924,38833,52226,53235,31824,69022,59229,24837,15855,09916,7881,8132,6334,0806,3168,3435,0663,0934,3373,1311,876
   Retained Earnings -339,931-302,335-274,642-275,706-262,238-244,585-231,839-222,472-160,456-128,305-114,961-99,736-79,795-50,957-38,798-35,85200000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
-1,955
-1,955
-8
-1
181
1,883
1,883
5,268
63,258
63,019
64,874
65,534
66,015
34,492
29,005
30,128
30,12829,00534,49266,01565,53464,87463,01963,2585,2681,8831,883181-1-8-1,955-1,95500000000
   Capital Surplus 000000000000000000000000
   Treasury Stock000000000000000000000000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.